Nextcure Inc Dossier - Source-backed chat

Nextcure Inc

NXTCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.07

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.96Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $22.7M

Enterprise Value $7.4M

Shares Outstanding 4.6M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NextCure, Inc. is undergoing a transformational strategic pivot from traditional monoclonal antibodies to high-value Antibody-Drug Conjugates (ADCs). The company's lead clinical assets, SIM0505 (targeting CDH6) and LNCB74 (targeting B7-H4), address significant unmet needs in gynecologic and other solid tumors. With positive Phase 1 dose-escalation data for SIM0505 presented at ASCO 2026 and an ongoing dose-optimization study, NextCure is well-positioned to deliver key clinical milestones. Backed by strategic partnerships with Simcere Zaiming and LigaChem Biosciences, and a cash runway extending into the first half of 2027, NextCure offers an attractive risk-reward profile for biotechnology investors seeking exposure to next-generation cancer therapeutics.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$20.00

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0015%

Clinical trials for SIM0505 or LNCB74 encounter dose-limiting toxicities or insufficient efficacy, halting development. The cash runway is depleted faster than expected, forcing highly dilutive equity financing or a severe pipeline contraction in a challenging capital-raising environment.

Base CaseCentral scenario

$15.0060%

SIM0505 successfully advances through its Phase 1 dose-optimization segment, confirming manageable safety and meaningful response rates in gynecologic cancers. LNCB74 dose escalation continues on track with a supportive trial update in H2 2026. The company maintains disciplined spending, keeping its cash runway intact into early 2027 while preparing for mid-stage clinical trials.

Bull CaseUpside scenario

$25.0025%

SIM0505 demonstrates exceptional efficacy and a best-in-class safety profile in the Phase 1 dose-optimization study for platinum-resistant ovarian cancer, leading to accelerated regulatory pathways. Concurrently, LNCB74's H2 2026 data readout shows robust anti-tumor activity, triggering milestone payments and attracting lucrative global co-development partnerships that fully fund the pipeline through registrational trials.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated ADC pipeline targeting validated cancer pathways (CDH6 and B7-H4) with advanced topoisomerase 1 and tubulin inhibitor payloads.
Strong clinical validation with positive Phase 1 dose-escalation data for SIM0505 presented at ASCO 2026, showing meaningful response rates.
Strategic collaborations with Simcere Zaiming and LigaChem Biosciences that share development costs and validate the platform's potential.
FDA Fast Track Designation for SIM0505 in platinum-resistant ovarian cancer, accelerating the regulatory and development timeline.

Key Investment Risks

High clinical development risk inherent to early-stage (Phase 1) oncology assets, which may fail to show sufficient efficacy or safety in larger cohorts.
Limited financial runway, with current cash resources expected to fund operations only into the first half of 2027, necessitating future capital raises.
Intense competition in the ADC space from both established pharmaceutical giants and well-funded biotechnology peers.

Thesis Invalidation Triggers

Failure of SIM0505 to demonstrate a competitive therapeutic window or sufficient efficacy in the Phase 1 dose-optimization study.
Severe safety concerns or unexpected toxicities emerging in the LNCB74 Phase 1 dose-escalation trial.
Inability to secure additional financing or strategic partnerships before the cash runway is depleted in early 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.